SavedAdd your journal

Journals / Düzce Üniversitesi Bilim ve Teknoloji Dergisi / 2022 / Cilt: 10 - Sayı: 2

(3-(4-chlorophenyl)-4,5-dihydroisoxazole-4,5-diyl)dimethanol Compound: Antibacterial Activity, Antifungal Activity and Calculated Structural Parameters

(3-(4-klorofenil)-4,5-dihidroizoksazol-4,5-diil)dimetanol Bileşiği: Antibakteriyel Aktivite, Antifungal Aktivite ve Hesaplanmış Yapısal Parametreler

Meryem PİR
Fatma BUDAK
Pages
815–822
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The structure of compound (1a) was drawn, and geometrical optimization was done using the Ab initio (RHF/3-21G) level.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We intended to quantify the antibacterial and antifungal activity results of 4,5-dihydroisoxazole dimethanol compound (1a) against several bacteria and fungi and also calculate some structural parameters (theoretical descriptors) of compound (1a) with this work.
📊
Key Findings & Data:Compound (1a) exhibited fair activities against all the bacteria and fungi.
💡
Conclusion & Impact:The structure of compound (1a) was drawn, and geometrical optimization was done using the Ab initio (RHF/3-21G) level.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Antimikrobiyal aktivite · Dihidroizoksazol dimetanol bileşiği · MİK

Abstract

We intended to quantify the antibacterial and antifungal activity results of 4,5-dihydroisoxazole dimethanol compound (1a) against several bacteria and fungi and also calculate some structural parameters (theoretical descriptors) of compound (1a) with this work. Microdilution broth procedures were studied using microdilution wells for the minimal inhibitory concentrations (MICs) test. Compound (1a) exhibited fair activities against all the bacteria and fungi. Compound (1a) has been a good result (MIC = 50 µg/ml) against particularly P. aeruginosa. The structure of compound (1a) was drawn, and geometrical optimization was done using the Ab initio (RHF/3-21G) level.

Özet

Bu çalışma ile, 4,5-dihidroizoksazol dimetanol bileşiğinin (1a) çeşitli bakteri ve mantara karşı antibakteriyel ve antifungal aktivite sonuçlarını ölçmeyi ve ayrıca (1a) bileşiğinin bazı yapısal parametrelerini (teorik tanımlayıcıları) hesaplamayı amaçladık. Mikrodilüsyon kuyucukları kullanılarak minimal inhibisyon konsantrasyonları (MİK) testi için mikrodilüsyon broth prosedürleri çalışılmıştır. Bileşik (1a), tüm bakteri ve mantara karşı etkili aktiviteler sergilemiştir. Bileşik (1a), özellikle P. aeruginosa'ya karşı iyi bir sonuç (MİK = 50 µg/ml) vermiştir. Bileşik (1a) 'nın yapısı çizilmiştir ve geometrik optimizasyonu Ab initio (RHF/3-21G) seviyesi kullanılarak yapılmıştır.

🔖

Cite This Article

PİR, M., BUDAK, F. (2022). (3-(4-chlorophenyl)-4,5-dihydroisoxazole-4,5-diyl)dimethanol Compound: Antibacterial Activity, Antifungal Activity and Calculated Structural Parameters. Düzce Üniversitesi Bilim ve Teknoloji Dergisi, Cilt: 10 - Sayı: 2, 815–822. https://ajindex.com/articles/493864

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. M. Serpi, Z. Özdemir, Y. Salman, “Investigation of the antibacterial effects of some plant extracts on Propionibacterium acnes,” KSU Journal of Agriculture and Nature, vol. 15, no. 1, pp. 7-12, 2012
  2. E. S. Bireller, A. B. Dinç, E. Şahin, A. Ergen, B. Çakmakoğlu, “Inverstigation of rational use of antibiotics on parents,” Experimed, vol. 6, no. 12, pp. 33-44, 2016
  3. D. L. Kiska, P. H. Gilligan, Pseudomonas. Manual of Clinical Microbiology, 7th ed., Washington, DC, USA: ASM Press., 1999, pp. 517-525
  4. A. U. Akbal, A. Y. Çoban, B. Durupınar, “New antibacterials,” Türk Mikrobiyoloji Cemiyeti Dergisi, vol. 48, no. 2, pp. 87-99, 2018
  5. K. Lewis, “New approaches to antimicrobial discovery,” Biochemical Pharmacology, vol. 134, pp. 87-98, 2017
  6. H. Krauss, A. Weber, M. Appel, Zoonoses. Infectious Diseases Transmissible from Animals to Humans, 3rd ed., vol. 194, Washington DC, USA: ASM Press, 2003, p. 456
  7. A. Waness, “Revisiting methicillin-resistant Staphylococcus aureus infections,” Journal of Global Infectious Diseases, vol. 2, no. 1, pp. 49-56, 2010
  8. A. E. Villaruz, J. B. Wardenburg, B. A. Khan, A. R. Whitney, D. E. Sturdevant, D. J. Gardner, F. R. DeLeo, M. Otto, “A point mutation in the agr locus rather than expression of the panton-valentine Leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation,” The Journal of Infectious Diseases, vol. 200, no. 5, pp. 724-734, 2009
  9. M. C. Enright, D. A. Robinson, G. Randle, E. J. Feil, H. Grundmann, B. G. Spratt, “The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA),” Proceedings of the National Academy of Sciences, vol. 99, no. 11, pp. 7687-7692, 2002
  10. G. Cornaglia, G. M. Rossolini, “Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens,” Clinical Microbiology and Infection, vol. 15, pp. 218-223, 2009
  11. U. Kayiş, “Antimicrobial Resistance Mechanisms,” ASD., vol. 5, no. 1, pp. 1-12, 2019
  12. A. Martinez, S. J. Kolvek, C. L. T. Yip, J. Hopke, K. A. Brown, I. A. Macneil, M. S. Osburne, “Genetically modified bacterial strains and novel bacterial artificial chromosome shuttle vectors for constructing environmental libraries and detecting heterologous natural products in multiple expression hosts,” Applied and Environmental Microbiology, vol. 70, no. 4, pp. 2452-2463, 2004
  13. A. Jabbour, M. Srebnik, B. Zaks, V. Dembitsky, D. Steinberg, “Evaluation of oxazaboroli